Daily Sabah logo

Politics
Diplomacy Legislation War On Terror EU Affairs Elections News Analysis
TÜRKİYE
Istanbul Education Investigations Minorities Expat Corner Diaspora
World
Mid-East Europe Americas Asia Pacific Africa Syrian Crisis Islamophobia
Business
Automotive Economy Energy Finance Tourism Tech Defense Transportation News Analysis
Lifestyle
Health Environment Travel Food Fashion Science Religion History Feature Expat Corner
Arts
Cinema Music Events Portrait Reviews Performing Arts
Sports
Football Basketball Motorsports Tennis
Opinion
Columns Op-Ed Reader's Corner Editorial
PHOTO GALLERY
JOBS ABOUT US RSS PRIVACY CONTACT US
© Turkuvaz Haberleşme ve Yayıncılık 2023

Daily Sabah logo

عربي
  • Politics
    • Diplomacy
    • Legislation
    • War On Terror
    • EU Affairs
    • Elections
    • News Analysis
  • TÜRKİYE
    • Istanbul
    • Education
    • Investigations
    • Minorities
    • Expat Corner
    • Diaspora
  • World
    • Mid-East
    • Europe
    • Americas
    • Asia Pacific
    • Africa
    • Syrian Crisis
    • Islamophobia
  • Business
    • Automotive
    • Economy
    • Energy
    • Finance
    • Tourism
    • Tech
    • Defense
    • Transportation
    • News Analysis
  • Lifestyle
    • Health
    • Environment
    • Travel
    • Food
    • Fashion
    • Science
    • Religion
    • History
    • Feature
    • Expat Corner
  • Arts
    • Cinema
    • Music
    • Events
    • Portrait
    • Reviews
    • Performing Arts
  • Sports
    • Football
    • Basketball
    • Motorsports
    • Tennis
  • Gallery
  • Opinion
    • Columns
    • Op-Ed
    • Reader's Corner
    • Editorial
  • TV
  • Life
  • Health
  • Environment
  • Travel
  • Food
  • Fashion
  • Science
  • Religion
  • History
  • Feature
  • Expat Corner

Pfizer, BioNTech partner up again to develop mRNA shingles vaccine

by French Press Agency - AFP

BERLIN Jan 05, 2022 - 4:43 pm GMT+3
A vial and syringe are seen in front of a Pfizer and BioNTech logo in an illustration, Jan. 11, 2021. (Reuters Photo)
A vial and syringe are seen in front of a Pfizer and BioNTech logo in an illustration, Jan. 11, 2021. (Reuters Photo)
by French Press Agency - AFP Jan 05, 2022 4:43 pm
RECOMMENDED
OpenAI's CEO Sam Altman, the founder of ChatGPT and creator of OpenAI, speaks at University College London, in London, U.K., May 24, 2023. (AP Photo)

Equal risk to nuclear war: Experts warn of extinction peril from AI

ARTIFICIAL-INTELLIGENCE

German pharmaceutical company BioNTech and its United States-based partner Pfizer, whose collaboration saw immense success in the development of a COVID-19 vaccine in record time with mRNA-based technology, said Wednesday that they are ready to partner up again, this time for a vaccine for the prevention of shingles using the same breakthrough technology.

The companies have signed a partnership deal and are aiming for clinical trials to start in the second half of 2022, they said in a joint statement. It is to be the first such vaccine based on messenger ribonucleic acid (mRNA) technology.

"The collaboration aims to develop a new mRNA-based vaccine against shingles, leveraging the expertise and resources of both companies," said Uğur Şahin, CEO and co-founder of BioNTech.

Shingles, which is also known as herpes zoster, is triggered by a virus that normally causes chickenpox in childhood. After that has cleared up, however, the virus remains in the nerve cells for life and can cause shingles at a later stage.

Typical symptoms of this include burning pain, followed by a spread of blisters on the skin. In rare cases, nerve pain can persist for long periods after the rash has cleared up.

The mRNA method made its debut with the Pfizer-BioNTech COVID-19 vaccine, which was the first jab against the coronavirus to be approved in the West in late 2020.

Another COVID-19 jab developed by United States rival Moderna also uses mRNA technology.

Scientists believe mRNA vaccines, which provoke an immune response by delivering genetic molecules containing the code for key parts of a pathogen into human cells, could be a game-changer against many diseases.

They also take less time to develop than traditional vaccines.

BioNTech's COVID-19 shot was developed and approved by regulators in less than a year.

BioNTech is also working on an mRNA-based malaria vaccine backed by the World Health Organization (WHO), the Africa Centers for Disease Control and Prevention and the European Union, with trials due to start in late 2022.

Shingles is a common disease around the world caused by reactivation of the same virus that causes chickenpox.

It can lead to extremely painful, disfiguring skin patches, and in rare cases, to facial paralysis, deafness and blindness.

While there are currently approved vaccines for shingles, Pfizer and BioNTech said they wanted to develop an improved vaccine that potentially shows high efficacy and better tolerability.

As with the COVID-19 vaccine, Pfizer will receive the right to market the potential vaccine worldwide, with the exception of Germany and Turkey – where BioNTech will hold the marketing rights – as well as some currently unspecified developing countries.

RECOMMENDED
OpenAI's CEO Sam Altman, the founder of ChatGPT and creator of OpenAI, speaks at University College London, in London, U.K., May 24, 2023. (AP Photo)

Equal risk to nuclear war: Experts warn of extinction peril from AI

ARTIFICIAL-INTELLIGENCE
  • shortlink copied
  • Last Update: Jan 05, 2022 7:32 pm
    RELATED TOPICS
    fight-against-terrorism DEUTSCHE-BANK US-LIBYA-RELATIONS
    KEYWORDS
    vaccines pfizer biontech uğur şahin mrna covid-19 pandemic shingles
    The Daily Sabah Newsletter
    Keep up to date with what’s happening in Turkey, it’s region and the world.
    You can unsubscribe at any time. By signing up you are agreeing to our Terms of Use and Privacy Policy. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
    U.S. President Joe Biden (C) gestures as he and Hunter Biden (L) watch fireworks from the Truman Balcony of the White House in Washington, D.C., U.S., July 2022. (EPA Photo)

    Hunter Biden's alleged iCloud leak exposes inappropriate content

    hunter-biden
    A general view of Dr. Sun Yat-sen's Mausoleum in Purple Mountai, Nanjing, China. (Photo courtesy by Ahmet Faruk Işık)

    Seed of modern Turkish diplomacy in China: Nanjing city

    Nanjing

    Turkish Airlines becomes world's 8th-strongest airline brand

    TURKISH-AIRLINES

    Erdoğan's triumph through the prism of Pakistan

    TURKISH-ELECTIONS
    No Image
    Forest fires hit Turkey's coastal resort areas
    PHOTOGALLERY
    • POLITICS
    • Diplomacy
    • Legislation
    • War On Terror
    • EU Affairs
    • News Analysis
    • TÜRKİYE
    • Istanbul
    • Education
    • Investigations
    • Minorities
    • Diaspora
    • World
    • Mid-East
    • Europe
    • Americas
    • Asia Pacific
    • Africa
    • Syrian Crisis
    • İslamophobia
    • Business
    • Automotive
    • Economy
    • Energy
    • Finance
    • Tourism
    • Tech
    • Defense
    • Transportation
    • News Analysis
    • Lifestyle
    • Health
    • Environment
    • Travel
    • Food
    • Fashion
    • Science
    • Religion
    • History
    • Feature
    • Expat Corner
    • Arts
    • Cinema
    • Music
    • Events
    • Portrait
    • Performing Arts
    • Reviews
    • Sports
    • Football
    • Basketball
    • Motorsports
    • Tennis
    • Opinion
    • Columns
    • Op-Ed
    • Reader's Corner
    • Editorial
    • Photo gallery
    • Jobs
    • privacy
    • about us
    • contact us
    • RSS
    © Turkuvaz Haberleşme ve Yayıncılık 2021